摘要
近年来促红细胞生成素(erythropoietin,EPO)的非造血生物作用逐渐引起关注。研究表明,EPO 可以减轻缺血缺氧时心肌细胞的损伤,减少心肌细胞的调亡,从而使其可能成为预防和治疗心肌缺血再灌注损伤的一条途径。
In recent years, the non-hematopoietic biological effects of erythropoietin (EPO) have drawn more attention. Some studies have demonstrated that EPO can mitigate cell damage and reduce myocardial tissue apoptosis under hypoxia/ischemia stress. EPO treatment can be a new pathway to protect the myocardial tissue from ischemia/reperfusion injury.
出处
《中国心血管杂志》
2007年第3期227-228,共2页
Chinese Journal of Cardiovascular Medicine